Rapport Therapeutics (RAPP) – Investment Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Rapport Therapeutics (NASDAQ: RAPP) in the last few weeks:

• 9/23/2026 – Rapport Therapeutics was given a new $80.00 price target by UBS Group AG.
• 9/23/2026 – Rapport Therapeutics had its “market outperform” rating reaffirmed by Citigroup Inc..
• 9/22/2026 – Rapport Therapeutics had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc..
• 9/16/2026 – Rapport Therapeutics had its price target raised by BTIG Research from $65.00 to $75.00. They now have a “buy” rating on the stock.
• 8/19/2026 – Rapport Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $65.00 price target on the stock.
• 8/17/2026 – Rapport Therapeutics had its “strong-buy” rating reaffirmed by Raymond James Financial, Inc.. They now have a $75.00 price target on the stock.
• 8/17/2026 – Rapport Therapeutics had its “strong-buy” rating reaffirmed by UBS Group AG.
• 8/12/2026 – Rapport Therapeutics had its price target raised by HC Wainwright from $40.00 to $66.00. They now have a “buy” rating on the stock.
• 8/8/2026 – Rapport Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 8/5/2026 – Rapport Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $65.00 price target on the stock.
• 7/28/2026 – Rapport Therapeutics is now covered by William Blair. They set an “outperform” rating on the stock.

Insider Activity at Rapport Therapeutics

In other news, CEO Abraham Ceesay sold 8,210 shares of the stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $45.61, for a total transaction of $374,458.10. Following the transaction, the chief executive officer directly owned 458,977 shares in the company, valued at $20,933,940.97. This represents a 1.76% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 81,244 shares of company stock valued at $3,858,615 over the last ninety days. 12.48% of the stock is owned by insiders.

Rapport Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines for disorders of the central nervous system. The company’s research centers on receptor-associated proteins, which help regulate neurotransmitter receptors and may provide opportunities to develop more selective therapies than those that target receptors broadly.

Rapport’s lead development program, RAP-219, is an orally administered investigational therapy designed to modulate AMPA receptors through their associated proteins.